MENU
+Compare
AIM
Stock ticker: ASE
AS OF
Jan 15, 04:05 PM (EDT)
Price
$1.32
Change
+$0.01 (+0.76%)
Capitalization
3.85M

AIM AIM ImmunoTech Inc. Forecast, Technical & Fundamental Analysis

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies... Show more

AIM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for AIM with price predictions
Jan 14, 2026

AIM in upward trend: price may ascend as a result of having broken its lower Bollinger Band on December 31, 2025

AIM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 43 cases where AIM's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 14, 2026. You may want to consider a long position or call options on AIM as a result. In of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for AIM just turned positive on January 05, 2026. Looking at past instances where AIM's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AIM advanced for three days, in of 211 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 39 cases where AIM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AIM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for AIM entered a downward trend on January 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.888) is normal, around the industry mean (27.929). P/E Ratio (0.000) is within average values for comparable stocks, (51.397). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.899). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.376) is also within normal values, averaging (329.547).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. AIM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AIM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
AIM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2117 SW Highway 484
Phone
+1 352 448-7797
Employees
28
Web
https://www.aimimmuno.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CNXC41.422.24
+5.72%
Concentrix Corp
CANG1.520.07
+4.83%
Cango
CSL359.132.71
+0.76%
Carlisle Companies
CMND2.450.01
+0.41%
Clearmind Medicine Inc.
PBHC14.23-0.13
-0.87%
Pathfinder Bancorp

AIM and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, AIM has been loosely correlated with URGN. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if AIM jumps, then URGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AIM
1D Price
Change %
AIM100%
+3.15%
URGN - AIM
39%
Loosely correlated
-5.50%
HOTH - AIM
33%
Loosely correlated
-0.48%
NEVPF - AIM
32%
Poorly correlated
N/A
RLYB - AIM
30%
Poorly correlated
-2.79%
SGMT - AIM
30%
Poorly correlated
+2.58%
More